Cart
sales@molnova.com
EP1-antagonist-1
CAS No. 851204-35-8
EP1-antagonist-1( EP1 antagonist 1 )
Catalog No. M26017 CAS No. 851204-35-8
EP1-antagonist-1 is an EP1 antagonist (pKi: 7.54; pIC50: 8.5).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 264 | Get Quote |
|
| 5MG | 404 | Get Quote |
|
| 10MG | 593 | Get Quote |
|
| 25MG | 888 | Get Quote |
|
| 50MG | 1251 | Get Quote |
|
| 100MG | 1692 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameEP1-antagonist-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionEP1-antagonist-1 is an EP1 antagonist (pKi: 7.54; pIC50: 8.5).
-
DescriptionEP1-antagonist-1 is an EP1 antagonist (pKi: 7.54; pIC50: 8.5).
-
In Vitro——
-
In Vivo——
-
SynonymsEP1 antagonist 1
-
PathwayOthers
-
TargetOther Targets
-
RecptorCleavable
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number851204-35-8
-
Formula Weight470.14
-
Molecular FormulaC19H15BrCl2N2O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCc1cc(nn1Cc1cc(Br)ccc1OCc1ccc(Cl)cc1Cl)C(O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Staben LR, et al. Stabilizing a Tubulysin Antibody-Drug Conjugate To Enable Activity Against Multidrug-Resistant Tumors. ACS Med Chem Lett. 2017 Sep 5;8(10):1037-1041.
molnova catalog
related products
-
mTOR inhibitor 9a
mTOR inhibitor 9a inhibited the growth of human LNCap cells with an ic50 of 80 nm. 1-methyl-3 -{4-[4-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)thieno[3,2-d]pyrimidin-2-yl]phenyl}urea may have antitumor activity.
-
(S)-VB 201
(S)-VB 201 is the S-enantiomer of VB 201.VB 201 oxidizes lipid compounds, has anti-inflammatory activity, and can be used for inflammation caused by coronavirus infection.
-
DL-Carnitine
Constituent of striated muscle and liver. It is used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias.
